Public Health England (PHE) has confirmed that three patients have been diagnosed with monkeypox in England. The first two patients are believed to have acquired the infection in Nigeria before travelling to the UK, while the third patient is a healthcare worker involved in the care of the second patient before monkeypox was diagnosed.
The first patient is a resident of Nigeria, and has received treatment at the Royal Free Hospital in London under strict isolation procedures. Prior to this, the patient was staying at a naval base in Cornwall. The second patient had travelled to Nigeria, and first presented to Blackpool Victoria Hospital, before being transferred to Royal Liverpool University Hospital for specialist care. The third patient is now isolated and is being looked after in a specialist unit at Royal Victoria Infirmary, Newcastle.
PHE said it would be contacting people who may have been in close contact with the individuals to provide information and health advice. The cases are the first ever diagnoses of monkeypox in the UK.
PHE has stressed that the infection does not spread easily between people and that the risk of transmission to the wider public is very low. However, it has produced guidance on diagnosis and treatment of the condition and commented that following a large sustained outbreak in Nigeria in 2017, monkeypox could continue to affect travellers returning from this area.
Human smallpox has been eradicated since 1977, but monkeypox is endemic in West and Central Africa.
If smallpox is suspected, the patient should be isolated immediately and the regional infectious diseases unit notified. All suspected cases should be managed by experts, including public health officials, to prevent a potential emergency situation. Monkeypox is also a notifiable condition.
Many other conditions present in a similar way, so it is important to keep in mind possible differentials as, since the eradication of smallpox, these are far more likely to be the cause.
Management is centred around isolation of the patient, infection control measures, and supportive care.
Smallpox is prevented by vaccination, and is only recommended for laboratory staff working with orthopox viruses, and public health and health care response team members.
Viruses belonging to the Poxvirus family (genus Orthopoxvirus ) that can naturally infect humans and mammals include variola virus (smallpox), monkeypox virus, vaccinia virus, cowpox virus, buffalopox virus, camelpox virus, and cantagalo virus. This topic focuses on human disease associated with smallpox and monkeypox infection.
Smallpox was a serious, contagious, and often fatal infectious disease caused by the variola virus. It was declared eradicated in 1980 following a global immunisation campaign led by the World Health Organization, with the last known natural case reported in Somalia in 1977. Smallpox infection generally resulted in acute onset fever and malaise, followed by a distinctive skin rash (i.e., raised firm lesions with umbilication) mainly occurring on the face, arms, and legs.  It was mainly transmitted between humans through the respiratory route (i.e., via saliva droplets); however, transmission from direct contact with infected bodily fluids was also reported. The incubation period of variola virus was 7 to 17 days with rash typically appearing 4 to 7 days later; the most infectious period was during the first week of illness. 
Monkeypox is a rare disease that is clinically nearly identical to smallpox, although usually less serious. There is one distinctive feature of monkeypox, which is marked lymphadenopathy.  The monkeypox virus can be transmitted to humans from different wild animals, such as non-human primates and rodents, although its natural host reservoir is unknown. Similar to smallpox, it can spread from human to human by the respiratory route or by direct contact with infected bodily fluids. The incubation period is usually 7 to 14 days, and disease typically lasts for 2 to 4 weeks. 
Consultant in Infectious Diseases
Department of Infectious Diseases and Tropical Medicine
North Manchester General Hospital
TB is the principal investigator on an MRC/Wellcome/Newton Fund grant to make a Zika vaccine based on recombinant modified vaccinia Ankara.
Professor of International Public Health
London School of Hygiene & Tropical Medicine
JW declares that he has no competing interests.
Epidemic Intelligence Service Officer
Poxvirus and Rabies Branch
Centers for Disease Control and Prevention
AS declares that she has no competing interests.
Use of this content is subject to our disclaimer